Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Oct 30, 2025. The company reported HK$0.098 earnings per share for the quarter, the consensus estimate of HK$0.098 by HK$0.

Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?

According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.272 which represents an annual dividend yield of 5.23%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here

What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.07.

How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.

What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.098 in its last earnings report, expectations of HK$0.098. Following the earnings report the stock price went down -0.372%.

Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:9989

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score

Neutral

Analyst Consensus

Moderate Sell

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

3.31%

Trailing 12-Months

Asset Growth

-6.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.